论文部分内容阅读
国家健康学会正在开始对淋巴细胞活化因子即:白细胞间素2(简称IL-2)第一期临床试用的研究。希望IL-2能恢复获得性免疫缺陷综合症(AIDS)病人的免疫系统的免疫功能。经许多组调查研究发现AIDS是一种免疫相关疾病,它是有免疫学方面特征。例如Quinan和他的同事们包括AIain和Rook发现患AIDS病人体内的细胞毒性T淋巴细胞对病毒感染的反应能力明显降低(细胞毒性T淋巴细胞具有特异杀伤原始被某些因子感
The National Institutes of Health is starting a first phase clinical trial of lymphocyte activation factor, interleukin 2 (IL-2). It is hoped that IL-2 will restore the immune function of the immune system in patients with Acquired Immune Deficiency Syndrome (AIDS). After many groups of investigations found that AIDS is an immune-related disease, it is immunologically characterized. For example, Quinan and colleagues, including AIain and Rook, found that cytotoxic T lymphocytes in patients with AIDS have a significantly reduced ability to respond to viral infections (cytotoxic T lymphocytes are specifically killed initially by some factor